Regulatory approval
Published by the Health Canada.
Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
This is written in the approval document as:
TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed |